Management of Febrile Neutropenia in Children

Initial Assessment and Stabilization

• The American Society of Clinical Oncology (ASCO) recommends that circulatory and respiratory function be assessed first, with vigorous resuscitation provided when needed, because infection signs may be minimal in neutropenic children, especially those receiving corticosteroids. 1
• ASCO advises drawing blood cultures from all lumens of any central venous catheter before starting antibiotics to maximize bacteremia detection. 2
• Chest radiography should be performed only in children who have respiratory symptoms (cough, dyspnea, abnormal lung exam); routine imaging in asymptomatic patients yields a low diagnostic yield (≤ 5%). 2

Risk Stratification

• A validated pediatric‑specific risk‑stratification tool should be applied immediately to classify patients as high‑risk or low‑risk for complications. 3
• High‑risk features (ASCO): acute myeloid leukemia or relapsed acute leukemia; highly myelosuppressive chemotherapy; allogeneic hematopoietic stem‑cell transplantation; expected prolonged neutropenia (> 10 days); hemodynamic instability or organ dysfunction. 2
• Low‑risk features (ASCO): solid tumors or standard‑risk leukemia in maintenance phase; expected brief neutropenia (< 7 days); clinically stable with no focal infection. 2

Empiric Antibiotic Therapy

High‑Risk Patients

• First‑line therapy should be monotherapy with an antipseudomonal β‑lactam (cefepime or piperacillin‑tazobactam) or a carbapenem (e.g., meropenem) after cultures are obtained. 2
• Addition of a second gram‑negative agent or vancomycin is reserved for clinically unstable patients, suspected resistant pathogens, or institutions with high rates of resistant organisms (e.g., MRSA, VRE). 2
• Selection of the initial agent must be guided by local antibiogram patterns. 1

Low‑Risk Patients

• When outpatient infrastructure exists, initial or step‑down outpatient management is appropriate, provided careful monitoring and reliable follow‑up can be ensured. 2
• Oral antibiotics may be used if the child can reliably tolerate oral intake. 2

Ongoing Management (24–72 h)

• The initial empiric regimen should not be altered solely because fever persists if the patient remains clinically stable. 2
• Double gram‑negative coverage or empiric vancomycin should be discontinued after 24–72 h when no microbiologic indication exists. 2
• If the patient becomes clinically unstable with persistent fever, broadening coverage to include resistant gram‑negative, gram‑positive, and anaerobic organisms is recommended. 2

Antibiotic Cessation

• For all patients with negative blood cultures at 48 h, who have been afebrile ≥ 24 h and show evidence of marrow recovery, empiric antibiotics may be stopped. 2
• For low‑risk patients, antibiotics may be discontinued at 72 h if cultures are negative and the child has been afebrile ≥ 24 h, even without documented marrow recovery, provided close outpatient follow‑up is arranged. 2

Empiric Antifungal Therapy (After 96 h)

High‑Risk for Invasive Fungal Disease (IFD)

• In children with high‑risk features (AML, relapsed leukemia, allogeneic HSCT, expected prolonged neutropenia > 10 days) who have persistent or recurrent fever after 96 h of broad‑spectrum antibacterials, empiric antifungal therapy should be started. 3
• Preferred agents are caspofungin or liposomal amphotericin B. Caspofungin is generally better tolerated, while liposomal amphotericin B is less nephrotoxic than conventional amphotericin B. 3
• CT imaging of the lungs and any clinically suspected sites should be performed to evaluate for invasive fungal disease. 2
• Serum galactomannan monitoring twice weekly is recommended in hospitalized high‑risk children for early detection of aspergillosis. 2

Low‑Risk for IFD

• In low‑risk neutropenic children with persistent fever, empiric antifungal therapy may be considered (weaker recommendation). Routine galactomannan screening is not recommended in this group. 2

Duration of Therapy

• Antifungal therapy should be continued until neutropenia resolves (absolute neutrophil count 100–500 µL) in the absence of documented or suspected invasive fungal disease. 3
• Antibacterial therapy duration depends on clinical response, culture results, and neutrophil recovery; in low‑risk patients meeting cessation criteria, therapy can be safely stopped at 72 h. 2

Management of Severe Neutropenia in Children

Initial Evaluation and Management

• Obtain blood cultures from all lumens of central venous catheters if present, as recommended by the American Society of Clinical Oncology, to increase detection of bacteremia 4
• Consider obtaining peripheral blood cultures concurrent with central venous catheter cultures to increase detection of bacteremia, as suggested by the American Society of Clinical Oncology 5
• Consider urinalysis and urine culture if a clean-catch specimen is readily available, as recommended by the American Society of Clinical Oncology 5, 6
• Obtain chest radiography only if respiratory symptoms are present, as recommended by the American Society of Clinical Oncology 5, 7

Risk Assessment and Immediate Management

• Evaluate for potential causes of neutropenia, including congenital disorders such as severe congenital neutropenia, cyclic neutropenia, and Shwachman-Diamond syndrome, as recommended by the American Society of Clinical Oncology 8
• Initiate empiric antibiotic therapy with monotherapy using an antipseudomonal β-lactam or carbapenem, such as piperacillin-tazobactam, cefepime, or meropenem, as recommended by the American Society of Clinical Oncology 5, 6

Ongoing Management and Monitoring

• Do not modify the initial empiric antibacterial regimen based solely on persistent fever if the child remains clinically stable, as recommended by the American Society of Clinical Oncology 4
• Consider antifungal therapy if fever persists beyond 96 hours of broad-spectrum antibiotics, especially if prolonged neutropenia is expected, as recommended by the American Society of Clinical Oncology 4
• For patients with neutropenia associated with malignancy, treat the underlying condition according to specific protocols, as recommended by the American Society of Clinical Oncology 8

Discharge Criteria and Home Management

• For low-risk patients with negative blood cultures who have been afebrile for at least 24 hours, consider discontinuation of empiric antibiotics at 72 hours, regardless of marrow recovery status, if careful follow-up can be ensured, as recommended by the American Society of Clinical Oncology 4
• For high-risk patients, continue antibiotics until blood cultures are negative at 48 hours, the patient has been afebrile for at least 24 hours, and there is evidence of marrow recovery, as recommended by the American Society of Clinical Oncology 4

Cautions and Pitfalls

• Do not rely on symptoms alone to identify infections in neutropenic patients, as inflammatory response may be blunted, as warned by the American Society of Clinical Oncology 5
• Do not delay antibiotic therapy while waiting for diagnostic test results in a febrile neutropenic child, as warned by the American Society of Clinical Oncology 5
• Recognize that pyuria may be absent in neutropenic patients with urinary tract infections, as noted by the American Society of Clinical Oncology 6
• Do not perform routine chest radiography in asymptomatic patients, as the yield is low (≤5%), as recommended by the American Society of Clinical Oncology 5, 7